ESM Fig. 1 Study flow diagram.

Entered run-in phase (n = 857)

Excluded (n = 280 [32.7%])
  - Refused to participate: 17 (2.0%)
  - Not meeting inclusion criteria: 234 (27.3%)
  - Other: 29 (3.4%)

Randomly assigned (n = 577)

Assigned to olmesartan (n = 288)
  - Dropped out (protocol violation) (n = 6)

Available for analysis (n = 282)
  - Dead 19
  - Alive 261
  - Lost to follow-up 2

Assigned to placebo (n = 289)
  - Dropped out (protocol violation) (n = 5)

Available for analysis (n = 284)
  - Dead 20
  - Alive 262
  - Lost to follow-up 2